Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com
Latest From iECURE, Inc.
Novartis is once again looking to be a pioneer in cell and gene therapy, though this time is selecting a potentially less complex administration method.
Many industry leaders expect broad progress in the field of RNA technologies following the rapid and successful roll-out of mRNA vaccines against COVID-19 last year. Genetic medicines of various types, emerging platforms for tackling previously “undruggable” targets and the microbiome were among other areas singled out as areas to watch in 2022.
Private Company Edition: Recent biopharma venture capital financings add up to $1.7bn, including a $135m crossover round for HilleVax after spinning out of Takeda in July to advance a norovirus vaccine, Skyhawk’s $133m in fresh funding and Obsidian’s $115m series B round.
Stock-and-cash deal valued at $229m brings AzurRx rights to niclosamide in additional indications. Boehringer Ingelheim partners with Twist on therapeutic antibody discovery.
- Gene Therapy, Cell Therapy